IN THE CLAIMS:

Please amend claim 1.

Please cancel claims 2, 3, 11, 14, 17, 20-26, 37, 38, 43, 65, 66, 68, 95, 120, 121, 123, 126, 167-171, 173, 175, 178, 199-203 on file without prejudice to the applicant's right to reinstate those claims or to pursue those claims in a continuation application. Claims 4-10, 12, 13, 15, 16, 18, 19, 27-36, 39-42, 44-46, 67, 69-94, 96-119, 122, 124, 125, 127-166, 172, 174, 176, 177, and 179-198 were previously cancelled. Accordingly, each of claims 2-203 are cancelled.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1. (**Currently amended**) A method for identifying an immunogenic protein or fragment thereof capable of eliciting an immune response, said method comprising ~~obtaining~~ providing a protein complex comprising an immunoglobulin and a protein or fragment thereof bound to said immunoglobulin by virtue of an antigen-antibody interaction, ~~or mixtures thereof or an immunoglobulin-containing fraction~~ wherein said protein complex has been obtained from a subject that has elicited an immune response against said immunogenic protein or fragment thereof or has been obtained from a cell, tissue or organ ~~thereof~~ of said subject, and identifying [[a]] said protein or fragment thereof bound to the immunoglobulin ~~by virtue of an antigen antibody interaction~~, thereby identifying an immunogenic protein or fragment thereof capable of eliciting an immune response.

2.-203. (**Cancelled**)

204. (**New**) The method according to claim 1, wherein the subject suffers from an infection or has suffered previously from an infection.

205. (**New**) The method according to claim 1, wherein the subject suffers from an autoimmune condition.

206. (**New**) The method according to claim 1, wherein the subject has been previously immunized with a cell or an extract thereof comprising the immunogenic protein or fragment thereof.

207. (**New**) The method according to claim 206, wherein the cell or extract thereof is derived from an infectious agent expressing the immunogenic protein or fragment thereof.

208. (**New**) The method according to claim 207, wherein the cell or extract thereof comprises a viral particle, a bacterial cell, a yeast cell, a fungal cell or a cell of a parasite or an extract from a virus, an extract from a bacterium, an extract from a yeast, an extract from a fungus, or an extract from a parasite.

209. (**New**) The method according to claim 208, wherein the cell is a bacterial cell or the cellular extract is a bacterial extract.

210. (**New**) The method according to claim 209, wherein the bacterial cell or bacterial extract is *Pseudomonas aeruginosa* or *Mycobacterium tuberculosis*.

211. (**New**) The method according to claim 1, additionally comprising separating an immunogenic protein or fragment thereof from the immunoglobulin of the protein complex.

212. (**New**) The method according to claim 211, wherein the immunogenic protein or fragment thereof is separated from the immunoglobulin by a method that comprises contacting the protein

complex with a compound that disrupts the antigen-antibody interaction for a time an under conditions sufficient to disrupt the antigen-antibody interaction.

213. (**New**) The method according to claim 212, wherein the compound that disrupts the antigen-antibody interaction is selected from the group consisting a compound that modulates the pH of the immunoglobulin fraction, a salt, an ionic detergent, a dissociating agent and a chaotropic agent.

214. (**New**) The method according to claim 1, additionally comprising isolating the protein or fragment thereof from the protein complex.

215. (**New**) The method according to claim 214, wherein the protein or fragment thereof is isolated using gel electrophoresis.

216. (**New**) The method according to claim 1, wherein the protein or fragment thereof is identified using mass spectrometry.

217. (**New**) The method according to claim 1, wherein the protein complex is obtained by a process comprising separating or purifying a sample from the subject.

218. (**New**) The method of claim 217, wherein separating or purifying comprises contacting the sample with one or more compounds capable of binding an immunoglobulin for a time and under conditions sufficient for binding to occur.

219. (**New**) The method of claim 218, further comprising isolating the one or more compounds.

220. (**New**) The method of claim 219, wherein the one of more compounds is/are previously immobilized on a solid support, matrix or resin.

221. (**New**) The method according to claim 220, further comprising washing the one or more immobilized compounds to thereby remove non-specifically bound protein or unbound protein.

222. (**New**) The method according to claim 218 further comprising linking immunoglobulin to the one or more compounds.

223. (**New**) The method according to claim 222 wherein linking comprises performing a process that comprises contacting a cross-linking agent with the one or more compounds having immunoglobulin bound thereto for a time and under conditions sufficient for covalent linkage to occur between a compound and the immunoglobulin.